Terms: = Lung cancer AND IGL
6 results:
1. igl CDR3 Hydropathy and Antigen Chemical Complementarity Associated with Greater Disease-Free Survival in lung Adenocarcinoma: Implications for Gender Disparities.
Charkowick SV; Huda TI; Patel DN; Yeagley M; Arturo JF; Cios KJ; Gozlan EC; Chobrutskiy A; Chobrutskiy BI; Blanck G
Biochem Genet; 2024 Feb; 62(1):530-546. PubMed ID: 37392243
[TBL] [Abstract] [Full Text] [Related]
2. Proteomic analysis of serum in workers exposed to diesel engine exhaust.
Rahman ML; Bassig BA; Dai Y; Hu W; Wong JYY; Blechter B; Hosgood HD; Ren D; Duan H; Niu Y; Xu J; Fu W; Meliefste K; Zhou B; Yang J; Ye M; Jia X; Meng T; Bin P; Silverman DT; Vermeulen R; Rothman N; Zheng Y; Lan Q
Environ Mol Mutagen; 2022 Jan; 63(1):18-28. PubMed ID: 34894159
[TBL] [Abstract] [Full Text] [Related]
3. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.
Remstein ED; Dogan A; Einerson RR; Paternoster SF; Fink SR; Law M; Dewald GW; Kurtin PJ
Am J Surg Pathol; 2006 Dec; 30(12):1546-53. PubMed ID: 17122510
[TBL] [Abstract] [Full Text] [Related]
4. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract] [Full Text] [Related]
5. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract] [Full Text] [Related]
6. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract] [Full Text] [Related]
